Pulmonx earnings date
Want to see LUNG full AI Analyst Report?
Pulmonx (LUNG) Q3 2026 Earnings Report
LUNG Q3 2026 EPS Results
- Actual EPS
- -$0.19
- Consensus EPS
- -$0.26
- Beat/Miss
- Beat by +$0.07
- One Year Ago EPS
- -$0.34
LUNG Q3 2026 Revenue Results
- Actual Revenue
- $22.84M
- Expected Revenue
- $21.93M
- Beat/Miss
- Beat by +$902.00K
- YoY Revenue Growth
- +6.20%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 10/27/2026
- Time
- After Close
- Conference Call
- Tuesday, October 27, 2026
Pulmonx's next earnings date is estimated for February 24, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was strongly constructive. Pulmonx returned to year-over-year revenue growth in both the U.S. and international businesses, improved gross margin, reduced operating expenses and losses, reiterated its full-year revenue outlook, and reported progress in its sales organization, clinical programs, China restart, and liquidity position. The main challenges were the relatively inexperienced salesforce, continued cash utilization and net losses, uncertainty around China's shipment timing, and the lack of 2027 guidance.
Pulmonx reiterated full year 2026 revenue guidance of $90 million to $92 million, now expects full year 2026 gross margin to be approximately 77%, operating expenses to fall between $108 million and $109 million, inclusive of approximately $14 million of noncash stock based compensation expense, and cash burn to be roughly $22 million, which would be a 30% reduction from our cash burn in 2025. Management expects year-over-year growth to continue for the remainder of the year, China shipments to resume by early next year, and CONVERT II IDE trial enrollment to be completed in the back half of next year; it expects AeriSeal to be commercial in Europe in 2027, with material revenues out of Europe with AeriSeal in 2028. Management said it is committed to sustaining double digit growth, expects OpEx to increase by maybe a few percent moving forward, expects to stay above 75% in terms of our gross margin profile, guides to about 40 a year in new accounts, and expects modest increases in the number of territories opportunistically.
- Return to Global Revenue GrowthThird-quarter 2026 total worldwide revenue was $22.8 million, up 6% from $21.5 million in the prior-year period on both a reported and constant-currency basis. This was Pulmonx's first return to global year-over-year growth since management rejoined the company last year.
- U.S. Revenue Growth and New Treating CentersU.S. revenue was $14.9 million, up 7% from $14 million in the prior-year period. Pulmonx added 8 new U.S. treating centers during the quarter and said the business grew sequentially despite typical third-quarter vacation-related seasonality.
- International Revenue GrowthInternational revenue was $7.9 million, up 5% from $7.5 million reported and up 6% on a constant-currency basis. Excluding China, international markets grew approximately 9% on both a reported and constant-currency basis.
- Improved Operating LeverageThird-quarter adjusted EBITDA loss declined nearly 60% to $3.5 million from $8.2 million in the prior-year period. Net loss declined 40% to $8.4 million from $14 million, while net loss per share improved to $0.19 from $0.34.
- Lower Operating ExpensesThird-quarter operating expenses were $24.9 million, down 18% from $30.4 million in the prior-year period. Excluding stock-based compensation, operating expenses decreased 16% year over year. The company attributed the decline to cost-reduction efforts initiated at the start of the year while maintaining investments in key growth initiatives.
- Full-Year Revenue and Expense Guidance ReiteratedPulmonx reiterated full-year 2026 revenue guidance of $90 million to $92 million and expects year-over-year growth to continue through the remainder of the year. Full-year operating expenses are now expected to be between $108 million and $109 million, inclusive of approximately $14 million of noncash stock-based compensation expense.
- Gross Margin ImprovementThird-quarter gross margin was 76%, compared with 75% in the prior-year period, driven by a lower mix of distributor sales in international markets and cost efficiencies across the supply chain. Full-year 2026 gross margin is now expected to be approximately 77%.
- Rebuilt U.S. Sales OrganizationPulmonx has substantially filled all open U.S. sales positions after focusing on rebuilding its sales leadership team and filling open territories. Management said the refocused commercial strategy and the rebuilt team are gaining traction and are expected to support continued growth.
- Progress in Commercial ExecutionThe company's near-to-far framework is emphasizing high-quality valve programs, physician education, targeted direct-to-patient efforts, and collaboration with service-line administrators. Pulmonx reported broad-based increases in account activity, including patient reviews, dedicated valve program coordinators, and systematic pulmonary-function-test reviews.
- Improved Digital Advertising EfficiencyPulmonx said it reduced cost per patient engagement in its digital advertising and is seeing increased yield from those engagements to successful treatment.
- Account Expansion and New-Account ActivityThe company guides to opening approximately 40 new accounts per year and said it was tracking slightly ahead of that level. Management also reported success from newer representatives in reactivating accounts that were not operating at full stride and in driving same-store sales.
- Clinical and Specialty-Society EngagementThe European Respiratory Society Congress featured a panel symposium and 19 poster presentations focused on bronchoscopic lung volume reduction, including patient pathways, patient experience, and multidisciplinary severe-COPD management. At the American Association of Bronchoscopy and Interventional Pulmonology meeting, five-year follow-up data from the LIBERATE pivotal trial was presented, along with multiple sessions on emerging uses of endobronchial valves.
- AeriSeal Market Expansion InitiativeEnrollment in the CONVERT II IDE trial continues to progress, and Pulmonx remains on track to complete enrollment in the back half of next year. Management believes AeriSeal could expand the company's global addressable market by roughly 20% and become a further revenue contributor.
- China Registration Renewal and Shipment RestartPulmonx secured renewal of its China registration certificate, restarted commercial activity in the region, and expects to resume shipments to its distributor by early next year. China is expected to represent about 2% of the business when it comes back online.
- Strong Liquidity and Debt Maturity ExtensionPulmonx ended September 30, 2026, with $52.7 million in cash and cash equivalents. The restructuring of its credit facility extended debt maturity to 2031 and provides access to an additional $20 million in undrawn capital subject to certain revenue milestones.
- Pathway Toward Cash-Flow BreakevenManagement expects gross margin to remain above 75%, including after China comes online, and said the combination of top-line growth, operating leverage, and available capital provides a clear pathway to cash-flow breakeven.
- Long-Term Growth CommitmentManagement remains committed to sustaining double-digit growth over the long term, while declining to provide a time frame. The company expects AeriSeal to be commercial in Europe in 2027 through a limited launch, with material European revenue anticipated in 2028.
LUNG Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 24, 2027 | 2026 (Q4) | -0.22- | -0.25 | ― | ― |
| Oct 27, 2026 | 2026 (Q3) | -0.26-0.19 | -0.34 | 44.12% (+0.15) | |
| Jul 29, 2026 | 2026 (Q2) | -0.28-0.24 | -0.38 | 36.84% (+0.14) | |
| Apr 29, 2026 | 2026 (Q1) | -0.33-0.33 | -0.36 | 8.33% (+0.03) | |
| Mar 04, 2026 | 2025 (Q4) | -0.39-0.25 | -0.33 | 24.24% (+0.08) | |
| Nov 12, 2025 | 2025 (Q3) | -0.42-0.34 | -0.36 | 5.56% (+0.02) | |
| Jul 30, 2025 | 2025 (Q2) | -0.39-0.38 | -0.39 | 2.56% (+0.01) | |
| Apr 30, 2025 | 2025 (Q1) | -0.40-0.36 | -0.36 | 0.00% (+0.00) | |
| Feb 19, 2025 | 2024 (Q4) | -0.45-0.33 | -0.36 | 8.33% (+0.03) | |
| Oct 30, 2024 | 2024 (Q3) | -0.45-0.36 | -0.39 | 7.69% (+0.03) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

